**Core tip:** This study highlights the fact that providing patients with realistic, but positive information about the expected effect of the treatment for irritable bowel syndrome is important to optimize the placebo response.

INTRODUCTION
============

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by recurrent episodes of abdominal pain, discomfort, and altered bowel habits that are not explained by structural or biochemical abnormalities\[[@B1]\]. Several pathophysiological mechanisms underlying IBS have been proposed. According to the bio-psycho-social model of IBS, a disturbance in intestinal motility and enhanced visceral sensitivity interact with other factors, such as environmental influences, parent-child interactions and disturbed stress responses\[[@B2]\].

Because of the limited effect of pharmacotherapy\[[@B3],[@B4]\], there has been increasing interest in psychological treatments for IBS. Two Cochrane reviews provided evidence for the effectiveness of cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT)\[[@B5]\] and hypnotherapy\[[@B6]\]. Another review\[[@B3]\] concluded that CBT, IPT and hypnotherapy, not relaxation therapy, were more effective than typical care in relieving IBS symptoms. In 2014, a systematic review showed that relaxation therapy was effective in reducing IBS symptoms\[[@B7]\].

In the research on psychological treatment methods, it is possible that the treatment effect is the result of increased attention and time investment on the patient rather than the therapy itself. In randomized controlled trials, a placebo group should be used to control for this effect. The placebo group is defined as a "matched control group participating in an activity regarded therapeutically inert from the theoretical perspective of the therapy under study"\[[@B8]\].

Although a placebo control is different in pharmacological studies than in psychological studies, they are equally important in both cases for achieving a methodologically valid comparison. In pharmacological research the placebo response rate (PRR) is variable and may be affected by the type, dosage, size, color, frequency, and route of administration of the placebo medication\[[@B9]\]. In psychological interventions, the PRR may result from the consultation itself and the relationship with the physician/therapist\[[@B10]\]. IBS patients experienced greater benefits from augmented, positive interaction with a practitioner than from limited or no interaction at all (*i.e*., being put on a waiting list)\[[@B10]\]. They also benefitted more from an increased number of office visits and a longer duration of treatment\[[@B11],[@B12]\], suggesting that supportive and empathic interaction with a practitioner might influence clinical outcomes. Placebo effects can be defined as "the beneficial effects that are attributable to the responses of the patient to the context in which the treatment is delivered, rather than to specific actions of the treatment"\[[@B13]\]. In RCTs in which psychological interventions are studied, a control intervention with an equal number and length of sessions, using an individual or a group format and with comparably trained of therapists\[[@B8]\] should be used to control for these effects. Currently, researchers who examine psychological interventions debate whether and to what degree the effects of psychotherapy are based on placebo effects or therapeutic factors\[[@B8],[@B14],[@B15]\].

From a methodological perspective, the PRR is viewed as an effect that needs to be corrected for. However, from a clinical perspective, a high PRR and a good treatment response are considered to be equally positive outcomes. From this perspective, when the PRR associated with psychological interventions is larger than associated with pharmacological interventions, the psychological placebo treatment may be of greater clinical relevance. The positive relationship with the therapist can be used as an additional beneficial factor.

We presumed that the placebo response would be greater in psychological interventions than in drug trials. So far, studies on the PRR in IBS have focused primarily on pharmacological treatments, treatment with dietary bran and complementary medicine. PRR rates in these studies ranged from 37.5% to 47%\[[@B11],[@B16]-[@B18]\].

One systematic review of alternative therapies for irritable bowel syndrome included a meta-analysis of psychological therapies\[[@B19]\]. A separate evaluation of the results of four of the 17 included studies that used a "true placebo group" was reported. The PRR of these four studies was 30.4%.

This study searched the MEDLINE database for articles published through 2001, sample sizes were low and the IBS criteria for the inclusion of studies were not defined. Since then, results of a number of new studies have been published. The present study aims to review systematically the PRR associated with different types of placebo control interventions in studies on psychological interventions in IBS and compare them to the PRR of placebo control interventions of drug trials.

MATERIALS AND METHODS
=====================

Inclusion and exclusion criteria
--------------------------------

**Types of studies:** Randomized controlled trials comparing psychological interventions for the treatment of IBS with a placebo control treatment that were written in English and published as a full text in a peer-reviewed journal, were eligible for inclusion. Cross-over studies were excluded, as were studies comparing two types of psychological therapeutic interventions without a placebo control.

**Types of participants:** Studies including male or female patients over the age of 18 years with IBS diagnosed according to Manning or Rome I, II or III criteria were included in the analysis.

**Types of interventions:** In accordance with earlier Cochrane reviews\[[@B5],[@B6]\], the following psychological interventions for the treatment of IBS were considered: stress management/relaxation therapy (cognitive) behavioral therapy, short-term psychodynamic therapy, and hypnotherapy.

**Types of placebo treatments:** Because of the potential impact of the format of the placebo intervention on the outcome\[[@B8]\], only studies with placebo-controlled interventions using the same number of sessions and therapeutic time as the active treatment were considered to be eligible for inclusion (For Baskin's other criteria, see Table [1](#T1){ref-type="table"}). Studies using a waiting list, usual care, symptom monitoring and therapeutic contact by phone or internet, were excluded.

###### 

Descriptive statistics for characteristics of included studies

  **Ref**.                        **Year**   **Country**                ***n***   **Mean age (yr)**   **Female sex**   **Recruitment**                                                                                       **Years of illness**   **Criteria**   **Therapy**                     **Control**                   **Format**                            **Ses-sions**   **Trained therapist intervention/placebo**   **Protocol inter-vention/placebo**
  ------------------------------- ---------- -------------------------- --------- ------------------- ---------------- ----------------------------------------------------------------------------------------------------- ---------------------- -------------- ------------------------------- ----------------------------- ------------------------------------- --------------- -------------------------------------------- ------------------------------------
  Craske et al\[[@B23]\] 2011     2011       United States              110       39.4                74               Community advertisement; university clinic                                                                                   RII            Cognitive-behavior-al therapy   Psycho-educatio-nal support   Individual                            10              Unclear/unclear                              Yes/yes
  Drossman et al\[[@B24]\] 2003   2003       United States and Canada   215       37.3                100              Community and hospital advertisement; physician referral in community or university-based practices                          R1             Cognitive-behavior-al therapy   Psycho-educational support    Unclear                               12              Yes/yes                                      Yes/yes
  Gaylord et al\[[@B25]\] 2011    2011       United States              75        42.7                100              Local advertisement; physician care                                                                                          RII            Mindful-ness                    Support                       Group                                 9               Yes/yes                                      Yes/yes
  Moser et al\[[@B26]\] 2013      2013       Austria                    100       45.5                79               Primary, secondary care and university clinic                                                         4/10.5                 RIII           Hypno-therapy                   Support                       Group                                 10              Yes/yes                                      Yes/no
  Payne et al\[[@B27]\] 1995      1995       United States              34        40.1                85               Personal physician                                                                                    16                     RI             Cognitive therapy               Psycho-educatio-nal support   Therapy: individual; Control: group   10              Yes/unclear                                  Yes/yes
  Shinozaki\[[@B28]\] 2010        2010       Japan                      21        31.6                52               University clinic                                                                                                                           Relax                           Psycho-educatio-nal support   Individual                            8               Yes/unclear                                  Yes/yes

**Types of outcome measures:** Studies were eligible for inclusion if they reported improvement in IBS symptoms and/or abdominal pain (measured with a validated IBS questionnaire) and/or adequate relief of abdominal pain and discomfort or satisfactory relief of IBS symptoms as recommended by the Rome III classification system for the design of IBS treatment trials\[[@B20]\].

Studies were excluded if no information on the effectiveness of the psychological interventions was available or if the proportion of patients in each group with overall symptom improvement after therapy was not reported.

Search methods to identify studies
----------------------------------

**Electronic searches:** We performed a systematic search of RCTs published from 1966 to February 2016 that were available in PubMed, Embase, the Cochrane Library, CINAHL and PsychINFO databases. The following search terms were used: "irritable bowel syndrome" \[MeSH\] OR "colonic diseases, functional" \[MeSH: NoExp\] OR "irritable bowel syndrome" \[tiab\] OR "irritable bowel syndromes" \[tiab\] OR "irritable colon" \[tiab\] OR "mucous colitis" \[tiab\] OR "ibs" \[tiab\] OR "functional colonic disease" \[tiab\] OR "functional colonic diseases" \[tiab\] OR "spastic colon" \[tiab\];

Combined with: ((cognitive\[tiab\] OR psychological\[tiab\] OR psychologic\[tiab\] OR psychodynamic\[tiab\] OR psychoanalytic\[tiab\] OR "psycho analytic"\[tiab\] OR stress\[tiab\] OR relaxation\[tiab\] OR conditioning\[tiab\] OR "problem solving"\[tiab\] OR interpersonal\[tiab\] OR "hypno analytic"\[tiab\] OR behavioral\[tiab\] OR behavioural\[tiab\] OR behavior\[tiab\] OR behaviour\[tiab\]) AND (therapy\[tiab\] OR therapies\[tiab\] OR treatment\[tiab\] OR treatments\[tiab\] OR intervention\[tiab\] OR interventions\[tiab\] OR management\[tiab\])) OR (psychotherapy\[tiab\] OR psychotherapies\[tiab\] OR psychoeducation\[tiab\] OR "psycho education"\[tiab\] OR psychoeducational\[tiab\] OR psychotherapy\[tiab\] OR hypnotherapy\[tiab\] OR hypnosis\[tiab\] OR hypnoses\[tiab\] OR hypnotism\[tiab\] OR hypnoanalysis\[tiab\] OR mesmerism\[tiab\] OR "hypno analysis"\[tiab\] OR autohypnosis\[tiab\] OR "auto hypnosis"\[tiab\] OR psychoanalyses\[tiab\] OR psychoanalysis\[tiab\] OR "psycho analysis"\[tiab\] OR biofeedback\[tiab\]) OR ("Behavior Therapy"\[MeSH\] OR "Psychoanalysis"\[MeSH\] OR "Psychoanalytic Therapy"\[MeSH\]). No filters or limits were used.

Data collection and analysis
----------------------------

**Study selection:** Two authors (CF and LB) reviewed the title and abstract of each identified article to determine the extent to which it met eligibility criteria, such as type of study, participants, interventions, placebo treatments and outcome measures, as described previously. A manual search of the references listed in the articles retrieved from the online search was performed to identify additional studies. The full texts of the selected articles were then reviewed by the same authors to assess eligibility based on the same criteria. Discrepancies between the selections made by CF and LB were resolved by a third author (NdW).

**Data extraction:** From the resulting selection of papers, information on the number of patients, patient characteristics (gender, mean age, and mean duration of illness), criteria for diagnosis (Rome I, Rome II, Rome III or Manning), treatment setting, intervention (type, group or individual delivery format, number of sessions, training of therapists and use of treatment/placebo manual), placebo control (type, group or individual delivery format, number of sessions, training of therapists and use of treatment/placebo manual), duration of treatment, duration of the follow-up period, and results relating to the primary and secondary outcome measures were extracted.

**Assessment of risk of bias:** The risk of bias assessment tool developed by the Cochrane Collaboration for RCTs\[[@B21]\] was used. The following sources of bias can be assessed with high, low or unclear bias ratings: adequate generation of the allocation sequence; concealment of allocation to conditions; blinding of participants and personnel; handling of incomplete outcome data; and selective outcome reporting. The percentage of patients who dropped out of the intervention and placebo control group as well as the results of the intention-to treat (ITT) analysis (when provided) were added.

Outcome measures
----------------

In this review, the post-treatment IBS symptom severity scores was the primary outcome measure. Most studies presented the results of the ITT analysis, although only one study included the results of the per protocol (PP) analyses. Secondary outcome measures were improvement of symptoms of anxiety and depression as well as quality of life. Quality of life was recommended as an outcome measure by the Rome III committee, whereas anxiety and depression were chosen as secondary outcome measures due to their high rates of co-morbidity\[[@B22]\].

Statistical analysis
--------------------

The response rate of the primary outcome measures was calculated by dividing the percentage of patients who responded according to the study criteria by the number of patients in the ITT analysis or who completed treatment. Relative placebo responses (Rel-PR) with 95% confidence intervals (95%CI) were calculated as the ratio of placebo response to active treatment response. Additionally, the mean Rel-PR across all studies was calculated.

The weighted average PRR was calculated by adding up the PRR per study multiplied by the number of patients in the placebo control group of that study and dividing the product by the total number of control patients in all of the studies.

Criteria for response evaluation were not available for the secondary measures; therefore, PRRs for the secondary outcome measures of anxiety, depression and quality of life were calculated by setting the response rate for these measures in the active arm at 100% and computing the response rate in the placebo arm as a relative percentage of the active arm. A relative response rate \> 100% indicated that the placebo intervention was more effective than the treatment intervention. To allow for comparison of the PRR between the primary and secondary outcome measures, we recalculated the rates for the primary outcome measures in this way.

For the secondary outcome measures, the PRR for the different types of placebo interventions were calculated by adding up the PRR per study multiplied with the number of patients in the placebo control group of that study and dividing the product by the total number of control patients in all of the studies.

RESULTS
=======

Description of studies
----------------------

The literature search resulted in the identification of 5169 studies. After screening the titles and abstracts, 112 studies were potentially eligible (see the flowchart in Figure [1](#F1){ref-type="fig"}). The manual search yielded no additional studies (Figure [1](#F1){ref-type="fig"}).

![Flowchart of studies selected. RCT: Randomized controlled trial.](WJG-23-2223-g001){#F1}

After reviewing the full manuscripts of these studies, 106 studies were excluded for various reasons (see the flowchart in Figure [1](#F1){ref-type="fig"}), leaving six eligible trials\[[@B23]-[@B28]\] that were included in the analysis. The characteristics of the included studies are shown in Table [1](#T1){ref-type="table"}. Sample sizes ranged from 21\[[@B21]\] to 215\[[@B24]\]. Patients were recruited from primary, secondary and tertiary care institutions, although they were also partially recruited through advertisements in three studies\[[@B23]-[@B25]\]. The treatment setting was unclear in two of the selected studies\[[@B25],[@B27]\] (Table [1](#T1){ref-type="table"}).

The mean age of the study populations ranged from 31.6 to 45.5 years. The proportion of female participants ranged from 52.4% to 100%. Only one study reported the duration of IBS\[[@B26]\]: a median of 4 years for the intervention group and 10.5 years for the placebo group. The duration of treatment and the placebo intervention ranged from 8 wk to 3 mo. The duration of the follow-up period ranged from 3 mo to 12 mo.

Quality assessment
------------------

Four of the six studies fulfilled almost all quality criteria (Table [2](#T2){ref-type="table"}).

###### 

Risk of bias ratings for included studies

  **Ref**.                        **Year**   **Random sequence generation**   **Allocation concealment**   **Blinding of participants and personnel**   **Blinding of outcome assessment**   **Incomplete outcome data**   **Selective reporting**   **Dropout treatment/placebo control (%)**             **ITT or PP**
  ------------------------------- ---------- -------------------------------- ---------------------------- -------------------------------------------- ------------------------------------ ----------------------------- ------------------------- ----------------------------------------------------- ---------------
  Craske et al\[[@B23]\] 2011     2011       Low                              Low                          Low                                          Low                                  Low                           Low                       Interoceptive Exposure:34; Stress Management: 36/16   ITT
  Drossman et al\[[@B24]\] 2003   2003       Low                              Low                          Low                                          Low                                  Low                           Low                       13/24                                                 ITT
  Gaylord et al\[[@B25]\] 2011    2011       Low                              Low                          Low                                          Low                                  Low                           Low                       6/18                                                  ITT
  Moser et al\[[@B26]\] 2013      2013       Low                              Low                          Low                                          Low                                  Low                           Low                       0/2                                                   PP
  Payne et al\[[@B27]\] 1995      1995       Unclear                          Unclear                      Low                                          Unclear                              Low                           Low                       0/0                                                   ITT
  Shinozaki\[[@B28]\] 2010        2010       Unclear                          Unclear                      High                                         High                                 Low                           Low                       0/0                                                   ITT

Possible ratings were low, high or unclear risk of bias. Studies with 2 control groups were rated twice for risk of bias because of lack of blinding (rated or active control groups appear in parentheses). ITT indicates that the analysis was intent-to-treat (analyzed as randomized). PP: Per protocol.

Type of placebo interventions
-----------------------------

Four studies used an educational program as the placebo intervention\[[@B23],[@B24],[@B27],[@B28]\]. In these studies, educational materials were provided and discussed with a therapist. In the study by Payne and Blanchard\[[@B27]\], individual cognitive therapy was compared to an educational placebo intervention delivered in a group format. The other studies compared individual CBT (with interoceptive exposure to visceral sensations) or stress management\[[@B23]\], individually delivered CBT\[[@B24]\] and autogenic training\[[@B28]\] to an individual educational placebo intervention.

Two studies on mindfulness and hypnotherapy delivered in a group format used support therapy as the placebo intervention\[[@B25],[@B26]\]. In the study by Gaylord et al\[[@B25]\] the placebo intervention sessions were facilitated by social workers who served as group leaders, focussing on specific predesigned topics and promoting open group discussions. The placebo intervention in the study by Moser et al\[[@B26]\] consisted of doctor's visits of the same duration as the treatment.

Placebo response
----------------

**Primary outcome measure:** One of the six studies investigated the effects of two separate psychological interventions and compared them with the effect of one placebo intervention\[[@B23]\], which brings the total number of outcomes to seven (see Table [3](#T3){ref-type="table"}). All studies reported a significant reduction in IBS symptoms for at least one of the treatment interventions. For the response rate for the primary outcome measure of the placebo and active intervention arms, see Table [3](#T3){ref-type="table"}. We performed the calculations using post-treatment figures. However, for the study by Craske et al\[[@B23]\], we used the figures at three-month follow-up because only they were reported.

###### 

Placebo treatment and placebo response rate

  **Ref**.                                      **Placebo treatment**        **Primary outcome measure**                       **Duration of treatment[1](#T3FN1){ref-type="table-fn"}**   **Follow-up**   **Placebo response**   **Treatment response**
  --------------------------------------------- ---------------------------- ------------------------------------------------- ----------------------------------------------------------- --------------- ---------------------- ---------------------------------------------
  Craske et al\[[@B23]\] 2011                   Psycho-educational support   BSS index                                         10 wk                                                       3 mo            59% (13/22)            62% (29/47)[1](#T3FN1){ref-type="table-fn"}
  54% (22/41)[2](#T3FN2){ref-type="table-fn"}                                                                                                                                                                                     
  Drossman et al\[[@B24]\] 2003                 Psycho-educational support   Composite score[3](#T3FN3){ref-type="table-fn"}   12 wk                                                                       37.3% (19/51)          70% (77/110)
  Gaylord et al\[[@B25]\] 2011                  Support group                IBS-SSS                                           8 wk                                                        3 mo            45.2% (17.6/39)        68.8% (27.4/36)
  53.1% (20.7/39)                               75% (27/36)                                                                                                                                                                       
  Moser et al\[[@B26]\] 2013                    Supportive talks             IBS-IS                                            12 wk                                                       12 mo           40.9%( 18/44)          60.8%(28/46)
  25% (11/44)                                   54.3% (25/46)                                                                                                                                                                     
  Payne et al\[[@B27]\] 1995                    Psycho-educational support   CPSR                                              8 wk                                                        3 mo            25% (3/12)             75% (9/12)
  18% (2/12)                                    83% (10/12)                                                                                                                                                                       
  Shinozaki\[[@B28]\] 2010                      Psycho-educational support   AR                                                8 wk                                                                        30% (3/10)             81.8% (9/11)

Cognitive behavioral treatment;

Stress management;

Composite score: Mc-Gill Pain Questionnaire; IBS-QOL; satisfaction with treatment; global well-being. IBS: Irritable bowel syndrome; BSS: Bowel syndrome severity index; IBS-SSS: IBS-Symptom Severity Score; IBS-IS: IBS-Impact Scale; AR: Adequate relief; CPSR: Composite primary symptom reduction.

Rel-PRs ranged from 0.33 (95%CI: 0.12--0.94) in the study by Payne and Blanchard\[[@B27]\] to 1.1 (95%CI: 0.7-1.73) in the study by Craske\[[@B23]\]. For details on the Rel-PRs, see Figure [2](#F2){ref-type="fig"}.

![Relative placebo responses defined as the ratio of placebo response to active treatment response in the individual studies. The mean relative placebo responses (Rel-PR) and 95% confidence intervals are shown. ^1^Cognitive behavioral treatment; ^2^Stress management. CBT: Cognitive behaviour therapy; CM: Contingency management; SM: Stress management.](WJG-23-2223-g002){#F2}

After adjusting for study sample size, the weighted average PRR for all studies was 41.4%. In subgroup analysis, after adjusting for study sample size, the pooled PRR was 39.5% for the educational programs and 42.9% for the supportive interventions, including doctor's visits\[[@B26]\].

**Secondary outcome measures:** Data on anxiety were presented in five studies\[[@B23],[@B25]-[@B28]\], whereas data on depression were provided in three studies\[[@B25],[@B27],[@B28]\]. Five studies assessed quality of life using the IBS-QOL or SF-36 as the outcome measure\[[@B23]-[@B26],[@B28]\]. The relative PRR for anxiety ranged from 0%\[[@B23],[@B27]\] to 267%\[[@B28]\]. The relative PRR for depression ranged from 6%\[[@B27],[@B28]\] to 52%\[[@B25]\]. For quality of life, it ranged from 20%\[[@B26]\] to 125%\[[@B23]\]. The relative placebo responses are presented in Table [4](#T4){ref-type="table"}.

###### 

Comparison of outcome measurements

  **Author**                                **Symptoms**                                 **Anxiety**                             **Depression**                     **Quality of life**
  ----------------------------------------- -------------------------------------------- --------------------------------------- ---------------------------------- ---------------------
  Craske CBT-IE                             Bowel Symptom Severity (BSS)                 VSI                                     \-                                 IBS-QOL (FA and IF)
  56%/89% = 63%                             0%/44% = 0%                                  \-                                      FA: 31/25 = 125%                   
  IF: 9/10 = 84%                                                                                                                                                    
  Craske SM                                 BSS                                          VSI                                     \-                                 IBS-QOL (FA and IF)
  56%/82% = 68%                             0%/23% = 0%                                  \-                                      FA: 31/17 = 184%                   
  IF: 9/14 = 64%                                                                                                                                                    
  Drossmann                                 Mc Gill pain Questionnaire                   \-                                      \-                                 IBS-QOL
  2.77/4.58 = 60%                           \-                                           \-                                      4.8/9.35 = 51%                     
  Gaylord                                   IBS-Symptom Severity Score                   VSI                                     Brief state inventory-depression   IBS-QOL
  (IBS-SSS)                                 Brief State Inventory-anxiety                                                                                           
  42.2/68.8 = 61%                           1.16/5.78 = 20%                              0.78/1.49 = 52%                         3.7/0.19 = 36%                     
  1.64/3.86 = 42%                                                                                                                                                   
  Moser                                     IBS-Impact Scale (IBS-IS)                    HADS                                    \-                                 SF-36
  Hospital Anxiety and Depression Scale                                                                                                                             
  40.9/60.8 = 67%                           0.5/3.7 = 14%                                \-                                      24/117.9 = 20%                     
  Payne and Blanchard                       Composite Primary Symptom Reduction (CPSR)   STAI (state)                            BDI                                \-
  STAI (trait)                                                                                                                                                      
  25%/75% = 33%                             FALSE                                        0.4/6.3 = 6%                            \-                                 
  FALSE                                                                                                                                                             
  Shinozaki                                 Adequate Relief                              State Trait Anxiety Inventory (state)   Self rating depression scale       SF-36
  Self Reported IBS Questionnaire (SIBSQ)   STAI (trait)                                 (SDS)                                                                      
  30/81.8 = 37%                             3.2/2.8 = 114%                               0.1/1.8 = 6%                            15.5/58.2 = 27%                    
  19.6/3.2 = 612%                           4/1.5 = 267%                                                                                                            

The percentages were calculated by dividing the treatment effect in the placebo group by the treatment effect in the intervention group and multiplying the quotient by 100. FA: Food avoidance; IF: Interference; VSI: Visceral sensitivity index.

With regard to the different types of placebo interventions, after adjusting for sample size, the weighted average sizes for the educational placebo interventions were 27.8% for state anxiety, 65.1% for trait anxiety, 6% for depression and 72.7% for quality of life. For the supportive interventions, they were 27.2% for anxiety, 52% for depression and 20.8% for quality of life.

DISCUSSION
==========

Summary of findings
-------------------

Our results showed that the PRR in six studies investigating the effect of psychological treatment on IBS for the primary outcome varied from 25.0% to 59.0%. The pooled adjusted mean PRR was 41.4%, which is comparable to the PRR reported in studies on pharmacological therapy (37.5%)\[[@B16]\]; medication and dietary fibre (47%)\[[@B18]\], medication and alternative medicine (40.7%)\[[@B17]\] and complementary medicine (42.6%)\[[@B11]\]. Our presumption that the response to placebo interventions in studies on psychological treatment for IBS would be greater than that to pharmacological interventions, was not confirmed by our results.

Explanation of findings
-----------------------

Compared to the placebo medication used in the pharmacological studies, the placebo interventions used in the psychological studies involved extensive patient-professional contact. It has been proposed\[[@B10],[@B29]\] that the personality of and empathy exhibited by the therapist during the placebo intervention are responsible for the placebo effect. Furthermore, the more time that the therapist spends with a patient, the greater the placebo response. Hence, one would expect that the PRR in psychological studies would be higher. The fact that we found comparable PRR to those reported in pharmacological studies is obviously inconsistent with this hypothesis. Other factors may need to be considered. Vase et al\[[@B30]\] showed that the combination of expected pain relief and desire for pain relief accounted for up to 81% of the variance in the effect of active treatment. They concluded that "adding a verbal suggestion for pain relief in drug treatment can increase the magnitude of placebo analgesia to that of an active agent." Kirsch\[[@B14]\] also argued that the placebo effect is generally dependent on the activation of response expectancy in the patient. From this perspective, the PRR is determined by the expectation of and desire for symptom relief of the patient, which is influenced by the way that the therapy is introduced and executed by the nurse, doctor or therapist. A positive interpersonal encounter with affective communication and adequate information from the health professional can positively influence the patient's expectations and result in an improvement in health status\[[@B31]\]. Therefore, the words that a general practitioner uses to create expectations within the patient are important, in both pharmacotherapy and psychological interventions\[[@B32]\]. The fact that we did not find a difference in placebo response in our study supports the idea that contextual factors and cognitive and emotional changes, such as expectancy, desire and memory play a role in the development of the placebo response\[[@B33]\].

Strengths and limitations
-------------------------

An important strength of the present study is the use of strict inclusion criteria to define IBS, psychological treatment\[[@B5],[@B6]\] and placebo control conditions. Although this approach also resulted in a small number of studies and a relatively low number of patients, we consider the comparability of the format of psychological and placebo intervention to be essential for a valid assessment of the "true" placebo effect.

Comparison to the literature
----------------------------

After adjusting for sample size, the pooled PR in the previous systematic review by Spanier et al\[[@B19]\] was 30.4%. Three of the four studies included in that analysis were excluded in this study, which involved different inclusion and exclusion criteria. Specifically, Blanchard et al\[[@B34]\] had no strict diagnostic criteria for IBS and Shaw et al\[[@B35]\] used usual care as the control intervention, which was not an appropriate control group according to our definition.

In a recent meta-analysis by Ford et al\[[@B36]\], 31 studies were included. Five of them were also included in our review, but we excluded the remaining 26 studies for the following reasons: the IBS criteria were not clear (2 studies) or Latimers criteria were used (1 study); it was not a randomized controlled trial (1 study); the intervention used was inappropriate according to our criteria \[self/management by a nurse (1 study), not by a therapist (2 studies), by e-mail (1 study)\]; or the control group did not fulfill the Baskin criteria \[symptom monitoring (7 studies), care as usual (6 studies), waiting list (1 study), medication (1 study) or not having the same number of therapeutic sessions (3 studies)\].

It would be interesting to compare the PRR of the psychological interventions for irritable bowel syndrome to that in studies on psychological interventions for other diseases. In the systematic review entitled "Psychological Interventions for treatment of inflammatory bowel disease" located in the Cochrane database and published in 2011\[[@B37]\], none of the control groups in the included studies met our criteria for control groups. In a study by Keefer et al\[[@B38]\] on gut-directed hypnotherapy for ulcerative colitis published in 2013, a control group that met our criteria was used. The placebo rate was 40%, which was comparable to the placebo rate found in our research. In a systematic review published in 2005, Enck and Klosterhalfen\[[@B12]\] compared the PRRs for functional bowel disorders with those of non-intestinal diseases and other organic gastrointestinal diseases. Most of the studies focused on drug treatment. The authors stated that the placebo effects in functional bowel disorders were similar to those in non-intestinal diseases (depression, pain and Parkinson's disease) and not too dissimilar to those in other gastrointestinal diseases (duodenal ulcer, inflammatory bowel disease).

Secondary outcome measures
--------------------------

The placebo effect on the secondary outcome measures differed considerably across studies. However, the overall trends showed the greatest effects on symptom scores and the smallest effects on quality of life, anxiety and depression, which is aligned with the findings reported by Vase et al\[[@B30]\]. Pain is the main complaint of IBS patients, and almost invariably these patients possess the hope and desire that treatment will bring relief of their IBS-related pain. The combination of expected pain relief and desire for pain relief generates the largest placebo effect, and consequently, the effect on symptom scores is likely to be the greatest.

The relatively high PRR for anxiety in the study of Shinozaki et al\[[@B28]\] (267%) may have been caused by the content of the educational program, which was completely focused on dietary education. Most IBS patients have considerable anxiety surrounding the potential for dietary substances to act as complaint-inducing agents. A program with this content is apparently helpful in reducing this anxiety. In the study by Craske et al\[[@B23]\], the educational program had a positive impact on the patients' food avoidance. Additionally, the effect on the Food Avoidance scale of the IBS-QOL scale was greater than the effects in the two treatment arms (125% and 184%). The results of these studies suggest that it may be worthwhile to include an educational module in IBS treatments.

In the study by Shinozaki et al\[[@B28]\], the PRR \> 100% of the Self-Reported IBS Questionnaire (SIBSQ) indicated that the placebo intervention was more effective than the treatment intervention. It is not clear why this study found a significant positive treatment effect of autogenic training on the primary outcome measure of "adequate relief" and a significant positive effect of the placebo intervention on the primary symptom measure SIBSQ.

Conclusions and clinical implications
-------------------------------------

In conclusion, despite the more extensive patient-professional contact, the PRR in the placebo arm of RCTs with psychological treatment interventions is comparable to that of RCTs on drug interventions. This finding does not support the hypothesis that the personality and empathy of the professional are the main determinants of the placebo effect. Most likely, the PR is determined to a greater extent by patient- than doctor-related factors. Particularly important is the combination of expectations about and desire for symptom relief, both of which are influenced by the way that the therapy is introduced and executed. Thus, for optimal control group comparison in studies investigating psychological treatment for IBS, patients in the control group should have similar expectations from the control intervention as patients in the active intervention arm. Therefore, future RCT's should map the expectations of patients in both RCT arms before starting the intervention.

In clinical practice, the placebo response can be used optimally by enhancing the expectations of the patient through the provision of realistic but positive information about the expected effect of the treatment. The preference of patients for a certain treatment might be related to the expected benefit, although it could also be the result of other contextual factors, such as the way in which the treatment is delivered (group versus individually). Future research should investigate the effect of patients' preference for a certain treatment arm on the treatment outcome.
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Background
----------

Irritable bowel syndrome (IBS) is a common chronic functional gastrointestinal disorder characterized by recurrent episodes of abdominal pain, discomfort, and altered bowel habits that cannot be explained by structural or biochemical abnormalities. Because of the limited effect of pharmacotherapy, there has been increasing interest in psychological treatments for IBS. As in pharmacological treatments, placebo effects play a role in psychological therapies. In psychological interventions, the placebo response may result from the consultation itself and the relationship with the physician/therapist. The authors presumed that the placebo response would be greater in psychological interventions than in drug trials. Therefore, the authors compared the placebo response rate in studies on psychological interventions for IBS with the placebo response rates in pharmacological studies.

Research frontiers
------------------

Awareness that proper assessment of the effect of psychological interventions for IBS requires comparison with a placebo treatment is growing. A number of randomized placebo-controlled trials on the effect of psychological interventions on IBS have been published.

Innovations and breakthroughs
-----------------------------

In previous meta-analyses on the placebo effect associated with psychological interventions for IBS, the criteria used for inclusion in the analyses have been liberal. For instance, some studies included patients who did not fulfill Rome criteria for IBS, whereas others used usual care as the control intervention. For our systematic review, the authors chose to include only randomized controlled trials (RCTs) that included a placebo intervention that met the strict prerequisites formulated by Baskin et al (2003).

Applications
------------

Contrary to our expectations, in our study we found that, despite the more extensive patient-professional contact, the response rate in the placebo arm of RCTs with psychological treatment interventions was comparable to that of RCTs with drug interventions. Thus, it seems that the personality and empathy of the professional are not the main determinants of the placebo effect. Instead, it appears that the placebo response is more determined by patient- than doctor-related factors. For optimal control group comparison in studies investigating psychological treatment for IBS, patients in the control group should have similar expectations from the control intervention as patients in the active intervention arm. Therefore, future RCTs should map the expectations of patients in both RCT arms before starting the intervention. Future research should also explore the effect of patients' preference for a certain treatment arm on the treatment outcome.

Terminology
-----------

The diagnosis of irritable bowel syndrome is made using consensus-based criteria, the most recent of which are the Rome criteria, recurrent abdominal pain associated with two or more of the following: (1) related to defecation; (2) associated with a change in the frequency of stool; and (3) associated with a change in the form (appearance) of stool. These criteria must have been fulfilled for the last 3 mo, with symptom onset occurring at least 6 mo prior to the diagnosis. A placebo is defined as an activity regarded therapeutically inert from the theoretical perspective of the therapy under examination.

Peer-review
-----------

Good, well-conducted study. Suggested to add that a supportive doctor-patient relationship with empathy and listening is likely to maximize the placebo response to pharmacological treatment, not only in IBS but also in other disease states.
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